# A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies

> **NCT01121991** · PHASE3 · COMPLETED · sponsor: **EMD Serono** · enrollment: 55 (actual)

## Conditions studied

- Infertility
- Ovarian Stimulation

## Interventions

- **DRUG:** Recombinant Human-Luteinizing Hormone (Luveris)

## Key facts

- **NCT ID:** NCT01121991
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2005-09
- **Final completion:** —
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2013-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01121991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01121991, "A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01121991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*